Table 1.
Consent for Pharmacogenomic Testing Across Various Patient Subgroups
| Consented to PG sampling (n = 1674) |
Did not consent to PG sampling (n = 1275) |
P | |
|---|---|---|---|
| Gender, n (%) | 0.04 | ||
| Male | 1021 (58) | 729 (42) | |
| Female | 653 (54) | 546 (46) | |
| Race, n (%) | 0.07 | ||
| White | 1214 (58) | 882 (42) | |
| African American | 293 (54) | 254 (46) | |
| Hispanic | 121 (57) | 90 (43) | |
| Asian | 21 (41) | 30 (59) | |
| Other | 25 (57) | 19 (43) | |
| Age, y, mean (SD) | 47.4 (7.9) | 47.6 (8.3) | 0.71 |
| Baseline HCV RNA, n (%) | 0.17 | ||
| >600,000 IU/mL | 1388 (57) | 1032 (43) | |
| ≤600,000 IU/mL | 286 (54) | 243 (46) | |
| METAVIR fibrosis score, n (%)* | 0.7 | ||
| F0 | 25 (54) | 21 (46) | |
| F1 | 1160 (58) | 857 (42) | |
| F2 | 235 (55) | 192 (45) | |
| F3 | 66 (55) | 54 (45) | |
| F4 | 112 (58) | 80 (42) | |
| Baseline smoking history, n (%)† | 0.39 | ||
| Current smoker | 620 (57) | 470 (43) | |
| Ex-smoker | 626 (58) | 455 (42) | |
| Non-smoker | 390 (54) | 327 (46) | |
| History of alcohol abuse, n (%) | 153 (58) | 109 (42) | 0.58 |
| History of depression, n (%) | 391 (57) | 299 (43) | 0.95 |
| History of diabetes, n (%) | 112 (57) | 85 (43) | 0.98 |
| History of hypertension, n (%) | 454 (57) | 342 (43) | 0.86 |
| History of coronary artery disease, n (%) | 25 (57) | 19 (43) | 0.99 |
*
Missing 76 of those who participated in pharmacogenomic testing and 71 of those who did not.
†
Missing 38 of those who participated in pharmacogenomic testing and 23 of those who did not.
Abbreviations: PG, pharmacogenomics testing.